Screener
Kymera Therapeutics KYMR EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Kymera Therapeutics’s reported figures.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
FAQ
- What is Kymera Therapeutics's EBITDA?
- Kymera Therapeutics (KYMR) reported EBITDA of -$73.58M in Q2 2026.
- How has Kymera Therapeutics's EBITDA changed year-over-year?
- Kymera Therapeutics's EBITDA increased by 10.8% year-over-year, from -$82.47M to -$73.58M.
- What is the long-term trend for Kymera Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Kymera Therapeutics's EBITDA has grown at a 36.5% compound annual growth rate (CAGR), from -$98.13M to -$341.09M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Kymera Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude